Sign In
Buy ALEC
$1.51
-0.110 (-6.79%)
At Close: Jul 31, 2026
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 08'th May 2025
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disea
Alector to Participate in Upcoming Healthcare Conferences
08:00am, Tuesday, 06'th May 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating p
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., Apri
Alector Provides Executive Leadership Update
04:05pm, Friday, 28'th Mar 2025
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
01:09am, Thursday, 27'th Feb 2025
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rose
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
06:55pm, Wednesday, 26'th Feb 2025
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 26'th Feb 2025
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 452
Alector to Participate in Upcoming Healthcare Conferences
08:00am, Tuesday, 25'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
04:05pm, Wednesday, 19'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
08:00am, Monday, 13'th Jan 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
02:20pm, Wednesday, 04'th Dec 2024
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
10:46am, Wednesday, 27'th Nov 2024
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
10:29am, Tuesday, 26'th Nov 2024
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's diseas
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
04:05pm, Thursday, 14'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has en
